Angiogenesis Inhibitors: all 4,430 studies that test it

Page 44 of 45. Open to participants first (542), then studies with results posted, then the rest; newest registration first within each.

• Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00033332Phase 3
• Radiation Therapy With or Without Thalidomide in Treating Patients With Brain MetastasesCompletedNCT00033254Phase 3
• CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous TherapyCompletedNCT00031941Phase 1
• Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With MelanomaCompletedNCT00031733Phase 2
• Thalidomide in Treating Anemia in Patients With Myelodysplastic SyndromeCompletedNCT00030550Phase 2
• Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast CancerCompletedNCT00028990Phase 3
• Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple MyelomaStatus unknownNCT00028886Phase 3
• Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic CancerCompletedNCT00028834Phase 2
• Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid TumorsCompletedNCT00028535Phase 1
• Phase II Bevacizumab + Tax In Advanced Breast CancerCompletedNCT00027885Phase 2
• Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant MesotheliomaCompletedNCT00027703Phase 2
• Halofuginone Hydrobromide in Treating Patients With Progressive Advanced Solid TumorsCompletedNCT00027677Phase 1
• Interferon Alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney CancerStatus unknownNCT00027664Phase 2
• Thalidomide in Treating Patients With Metastatic Neuroendocrine TumorsCompletedNCT00027638Phase 2
• APC8015 and Bevacizumab in Treating Patients With Prostate CancerCompletedNCT00027599Phase 2
• Thalidomide in Treating Patients With Thyroid CancerCompletedNCT00026533Phase 2
• Interferon Alfa and Thalidomide in Treating Patients With Stage IV MelanomaCompletedNCT00026520Phase 2
• Interferon Alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone SarcomaStatus unknownNCT00026416Phase 2
• SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate CancerCompletedNCT00026377Phase 1
• SU5416 in Treating Patients With Persistent or Recurrent Cervical CancerCompletedNCT00026260Phase 2
• Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's LymphomaCompletedNCT00026182Phase 2
• Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant MelanomaCompletedNCT00026143Phase 2
• Thalidomide in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT00025467Phase 2
• Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung CancerCompletedNCT00025389Phase 2
• Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously TreatedCompletedNCT00025337Phase 3
• Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00025285Phase 2
• Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the UterusCompletedNCT00025220Phase 2
• Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck CancerCompletedNCT00023959Phase 1
• Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous LeukemiaTerminatedNCT00023920Phase 2
• Radiation Therapy With or Without SU5416 in Treating Patients With Soft Tissue SarcomaCompletedNCT00023725Phase 1/2
• Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00022607Phase 2
• Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00022581Phase 2
• Bevacizumab in Treating Patients With Myelodysplastic SyndromeCompletedNCT00022048Phase 1/2
• Squalamine Lactate Plus Carboplatin in Treating Patients With Recurrent or Refractory Stage III or Stage IV Ovarian CancerStatus unknownNCT00021385Phase 2
• Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung CancerCompletedNCT00021060Phase 2/3
• Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00020449Phase 2
• Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate CancerCompletedNCT00020046Phase 2
• Interleukin-12 in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00019188Phase 1/2
• Thalidomide in Treating Patients With HIV-Associated Kaposi's SarcomaCompletedNCT00019123Phase 2
• Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast CancerCompletedNCT00017394Phase 2
• Thalidomide and SU5416 in Treating Patients With Metastatic MelanomaCompletedNCT00017316Phase 2
• Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast CancerCompletedNCT00016549Phase 2
• Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal CancerCompletedNCT00016289Phase 2
• Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian CancerCompletedNCT00016224Phase 2
• Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate CancerCompletedNCT00016107Phase 2
• S0108 Bevacizumab in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00016094Phase 2
• Thalidomide in Treating Patients With Myelodysplastic SyndromeCompletedNCT00015990Phase 2
• Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00015977Phase 2
• Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic CancersCompletedNCT00015951Phase 2
• Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedNCT00015912Phase 2
• Thalidomide in Treating Patients With MyelofibrosisCompletedNCT00015821Phase 2
• Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant GliomaTerminatedNCT00014443Phase 2
• SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous TreatmentTerminatedNCT00009919Phase 2
• Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple MyelomaCompletedNCT00008242Phase 2
• Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple MyelomaCompletedNCT00006890Phase 2
• Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal CancerCompletedNCT00006786Phase 2
• SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and NeckCompletedNCT00006361Phase 2
• Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain TumorCompletedNCT00006358Phase 2
• Treatment of Hepatocellular Carcinoma With TetrathiomolybdateCompletedNCT00006332Phase 2
• SU5416 in Treating Children With Recurrent or Progressive Brain TumorsTerminatedNCT00006247Phase 1
• Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic LeukemiaCompletedNCT00006226Phase 2
• Thalidomide and Dacarbazine for Metastatic MelanomaStatus unknownNCT00006200Phase 2
• Chronic Thalidomide Administration in Patients Undergoing Chemoembolization for Unresectable Hepatocellular CancerStatus unknownNCT00006198Phase 2
• SU5416 and Carboplatin to Treat Ovarian CancerCompletedNCT00006155Phase 1
• Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by SurgeryCompletedNCT00006016Phase 2
• SU5416 in Treating Patients With Malignant MesotheliomaCompletedNCT00006014Phase 2
• SU5416 in Treating Patients With Refractory or Relapsed Multiple MyelomaCompletedNCT00006013Phase 2
• Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically RemovedCompletedNCT00006006Phase 2
• Thalidomide in Treating Patients With Gynecologic SarcomasCompletedNCT00006005Phase 2
• SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously TreatedTerminatedNCT00006003Phase 2
• SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal CancerTerminatedNCT00006001Phase 2
• Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney CancerCompletedNCT00005966Phase 3
• Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial TherapyCompletedNCT00005942Phase 1/2
• SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to TreatmentCompletedNCT00005931Phase 2
• SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue SarcomasCompletedNCT00005862Phase 2
• S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple MyelomaTerminatedNCT00005834Phase 3
• SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast CancerCompletedNCT00005822Phase 1
• SU5416 and Irinotecan in Treating Patients With Advanced Colorectal CancerCompletedNCT00005818Phase 1/2
• Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00005815Phase 1/2
• Safety of the Candidate Vaccine C4-V3 Alone or With Interleukin-12 (IL-12) in HIV-Infected Patients Receiving Effective Anti-HIV Drug TherapyCompletedNCT00005779Phase 1
• SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and NeckCompletedNCT00005647Phase 1
• SU5416 in Treating Patients With Advanced Solid TumorsCompletedNCT00005642Phase 1
• Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid TumorsCompletedNCT00005604Phase 1
• Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Solid TumorsCompletedNCT00005061Phase 1
• SU5416 in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00005042Phase 2
• Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast CancerCompletedNCT00004893Phase 2
• Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial CancerCompletedNCT00004876Phase 2
• Endostatin in Treating Patients With Advanced Refractory Solid TumorsCompletedNCT00004872Phase 1
• SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation TherapyCompletedNCT00004868Phase 1/2
• Randomized Study of Beta Interferon and Thalidomide in Patients With AdrenoleukodystrophyCompletedNCT00004450Not applicable
• Study of Tetrathiomolybdate in Patients With Wilson DiseaseCompletedNCT00004339Phase 3
• Phase II Placebo Controlled Study of Thalidomide in Patients With Mycobacterial and HIV InfectionsCompletedNCT00004276Phase 2
• Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00004260Phase 1
• Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant MelanomaCompletedNCT00004244Phase 1
• Endostatin in Treating Patients With Advanced Solid TumorsCompletedNCT00004229Phase 1
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
• Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck CancerCompletedNCT00004070Phase 1/2
• Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow TransplantCompletedNCT00003894Phase 2
• Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00003850Phase 2
• Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood CancersCompletedNCT00003754Phase 2

← Angiogenesis Inhibitors overview